Adagene and Incyte form alliance to target treatment-resistant colorectal cancer
Adagene (NASDAQ:ADAG) and Incyte (NASDAQ:INCY) have entered into a clinical trial collaboration to evaluate a potent combination of immunotherapy agents in patients with microsatellite stable colorectal cancer (MSS CRC), a disease state notoriously resistant to standard immune checkpoint inhibitors.


-640x360.webp&w=3840&q=75)








